NAFDAC Guidelines on Variation to a Registered Vaccine for Humans
Guideline · Technology
Guidelines outline procedures for managing changes to registered human vaccines, focusing on biological product manufacturing complexities. They target regulated entities, NAFDAC teams, and industry stakeholders. This ensures modifications do not compromise vaccine safety, immunogenicity, or quality.
NAFDAC Guidelines on Variation to a Registered Vaccine for Humans
What Is This Policy?
Guidelines for managing post-registration changes to approved human vaccines, with specific provisions reflecting the complexity of biological product manufacturing.
Who Does It Target?
Vaccine manufacturers and importers of registered human vaccines seeking post-approval changes; vaccine regulatory affairs specialists; NAFDAC's biologics and vaccines evaluation teams; the National Primary Health Care Development Agency (NPHCDA)
NAFDAC teams Industry stakeholders
What Does It Aim to Achieve?
Ensure that modifications to registered vaccines do not compromise safety, immunogenicity, or quality.
Key Features
Variation Types: Categories specific to biological products including manufacturing process changes and new presentations Comparability Studies: Requirements for demonstrating that post-change products are comparable to the approved version Stability Data: Updated stability studies supporting changed products
Current Status
Rollout Stage: Active Coverage: All applicable entities Lead Agency: NAFDAC
How to Access
Regulated entities must comply. Classify the proposed change Conduct comparability studies where required Submit variation application with supporting data
Official Resources
Website: nafdac.gov.ng Contact: NAFDAC, Abuja
Legal Framework
Issued under the National Agency for Food and Drug Administration and Control Act 1993 (as amended). Operates alongside the Food and Drugs Act Cap F32 LFN 2004, the Pharmacists Council of Nigeria Act, the ICH Good Manufacturing Practice guidelines, WHO prequalification standards, and the Falsified Medicines guidelines adopted by Nigeria. Draws on WHO guidelines for the variation of a prequalified vaccine dossier and ICH Q5E comparability guidelines for biological products.